CN108310013A - A kind of compound and preparation method thereof for treatment of arthritis - Google Patents
A kind of compound and preparation method thereof for treatment of arthritis Download PDFInfo
- Publication number
- CN108310013A CN108310013A CN201810200703.7A CN201810200703A CN108310013A CN 108310013 A CN108310013 A CN 108310013A CN 201810200703 A CN201810200703 A CN 201810200703A CN 108310013 A CN108310013 A CN 108310013A
- Authority
- CN
- China
- Prior art keywords
- blood
- plasma
- blood plasma
- volume
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 80
- 150000001875 compounds Chemical class 0.000 title claims abstract description 79
- 238000011282 treatment Methods 0.000 title claims abstract description 61
- 206010003246 arthritis Diseases 0.000 title claims abstract description 35
- 210000002381 plasma Anatomy 0.000 claims abstract description 364
- 239000008280 blood Substances 0.000 claims abstract description 84
- 210000004369 blood Anatomy 0.000 claims abstract description 83
- 239000000654 additive Substances 0.000 claims abstract description 36
- 230000000996 additive effect Effects 0.000 claims abstract description 34
- 239000000470 constituent Substances 0.000 claims abstract description 27
- 210000001772 blood platelet Anatomy 0.000 claims description 54
- 230000010355 oscillation Effects 0.000 claims description 40
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 29
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 29
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 29
- 150000002632 lipids Chemical class 0.000 claims description 25
- 230000000735 allogeneic effect Effects 0.000 claims description 21
- 108010094028 Prothrombin Proteins 0.000 claims description 20
- 102100027378 Prothrombin Human genes 0.000 claims description 20
- 201000008482 osteoarthritis Diseases 0.000 claims description 19
- 229940039716 prothrombin Drugs 0.000 claims description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 18
- -1 blood platelet Proteins 0.000 claims description 18
- 239000002002 slurry Substances 0.000 claims description 14
- 239000006166 lysate Substances 0.000 claims description 12
- 102000009027 Albumins Human genes 0.000 claims description 11
- 108010088751 Albumins Proteins 0.000 claims description 11
- 102100030563 Coagulation factor XI Human genes 0.000 claims description 10
- 108010074864 Factor XI Proteins 0.000 claims description 10
- 108010071289 Factor XIII Proteins 0.000 claims description 10
- 108010049003 Fibrinogen Proteins 0.000 claims description 10
- 102000008946 Fibrinogen Human genes 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 10
- 229940012952 fibrinogen Drugs 0.000 claims description 10
- 108010074605 gamma-Globulins Proteins 0.000 claims description 10
- 230000002779 inactivation Effects 0.000 claims description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 10
- 239000003223 protective agent Substances 0.000 claims description 10
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 9
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 9
- 102100029117 Coagulation factor X Human genes 0.000 claims description 9
- 108010076282 Factor IX Proteins 0.000 claims description 9
- 108010023321 Factor VII Proteins 0.000 claims description 9
- 108010054218 Factor VIII Proteins 0.000 claims description 9
- 102000001690 Factor VIII Human genes 0.000 claims description 9
- 108010014173 Factor X Proteins 0.000 claims description 9
- 229910021529 ammonia Inorganic materials 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 201000003068 rheumatic fever Diseases 0.000 claims description 7
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 6
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 229960000182 blood factors Drugs 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 5
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 5
- 229960000905 indomethacin Drugs 0.000 claims description 5
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 5
- 229960001225 rifampicin Drugs 0.000 claims description 5
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 4
- 108010024636 Glutathione Proteins 0.000 claims description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 4
- 229960003677 chloroquine Drugs 0.000 claims description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
- 229960004618 prednisone Drugs 0.000 claims description 4
- 240000004307 Citrus medica Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229960003350 isoniazid Drugs 0.000 claims description 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 3
- 230000003534 oscillatory effect Effects 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000008227 sterile water for injection Substances 0.000 claims description 2
- 102100030556 Coagulation factor XII Human genes 0.000 claims 4
- 108010014172 Factor V Proteins 0.000 claims 4
- 108010080865 Factor XII Proteins 0.000 claims 4
- 239000004023 fresh frozen plasma Substances 0.000 claims 4
- 230000002917 arthritic effect Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 9
- 208000032839 leukemia Diseases 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 3
- 230000003796 beauty Effects 0.000 abstract description 2
- 238000005094 computer simulation Methods 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 abstract description 2
- 238000009533 lab test Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 238000007493 shaping process Methods 0.000 abstract 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 35
- 238000000034 method Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 11
- 208000014951 hematologic disease Diseases 0.000 description 10
- 239000012503 blood component Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 230000008439 repair process Effects 0.000 description 9
- 235000015110 jellies Nutrition 0.000 description 8
- 239000008274 jelly Substances 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 239000003114 blood coagulation factor Substances 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 229940012444 factor xiii Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000009832 plasma treatment Methods 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003914 blood derivative Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000005067 joint tissue Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 241001421185 Anomis Species 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The compound and preparation method thereof that the present invention relates to a kind of for treatment of arthritis belongs to medicine, corrects skin and shaping and beauty technical field；The proportioning of blood plasma is as follows：Including universal blood plasma and blood constituent additive；Wherein, universal blood plasma is universal fresh frozen blood plasma or universal frozen dry blood plasma；For universal fresh frozen blood plasma and universal frozen dry blood plasma, formed by the blood group blood plasma mixed preparing of following volumes part：A type blood plasma：5 10 parts by volume；Type B blood plasma：27 parts by volume；O-shaped blood plasma：0.5 3 parts by volume；AB type blood plasma：0.5 3 parts by volume.For decrease of platelet, leukaemia people and other arthritic patients, the multi-functional human plasma of case-involving application for a patent for invention can then be applied, it can be matched according to blood testing result and joint fluid result of laboratory test input computer model, then be allocated in vitro, be injected into human synovial intracavitary.
Description
Technical field
The compound and preparation method thereof that the present invention relates to a kind of for treatment of arthritis belongs to medicine, treatment arthritis
The orthopaedic techniques field such as pain and reparation joint.
Background technology
Osteoarthritis (Osteoarthritis, OA) is a kind of common, multiple, degenerative disease, typical pathologic
Occur characterized by articular cartilage damage, the change of subchondral bone structure and spur etc..At present in China 60 years old or more old man, just have
55% people suffers from Osteoarthritis, illness rate with the age increase ascendant trend year by year.As China progresses into aging
The extension of society and Chinese's average life span, now there are about the torments that 1.2 hundred million people are undergo Osteoarthritis.Due to office
Portion's blood supply is bad and autogenous bone marrow stem cell lesion, and the autosynthesis repair ability of usual Osteoarthritis is limited, such as
Therapy intervention is not leaned on, the reparation in joint and the recovery of function are cannot achieve.Drug therapy and operation can only also be alleviated to a certain degree
The state of an illness, cannot play the function of Regeneration and Repair, and most of patient to late period will inevitably perform the operation row prosthetic replacement.
In recent years, regenerative medicine field achieves significant progress, the reason is that seeking that tissue deterioration is reduced or avoided
Novel method for the treatment of.Tissue deterioration can be caused by consume, aging or disease.One very important part of these progress, packet
Include and be referred to as " it is self ' certain preparations of (autologous) compound or the exploitation of compound.The feature of self compound exists
Patient itself (such as blood from patient) is come from them.Self compound is seeking the medical treatment using patient's own resource
It is gradually developed in solution, is the possibility in order to avoid rejection.In addition, it has been observed that using certainly in clinical practice
Compound made from body compound rather than general substance (not obtained from patient itself), also can improve and tissue is accelerated to repair
It is multiple, because they provide the bioactive molecule for participating in and accelerating self-healing procedure.Self compound is characterized in that they are raw
Object is compatible.That is, body identifies that they are all for itself.Also, self compound be it is biodegradable, they
Natural by-product (subproduct) or metabolite are discharged in its internal degradation process, they can enhance rather than interfere reparation
(synthesis compound is not then that may cause to interfere in this way, the product that generates not is generated by body itself when they degrade to mechanism
Even preventing the inflammatory reaction of regenerative process).Self compound is also bionical.That is, the phase of they and host tissue
Interaction Simulation physiology repair mechanism.Another rare molecule complexity for being characterized in them of self product：They are
Polymolecular compound, the different phase of molecules influence repair process.To reach effect same with sintetics, that is to say, that
Design and Implement the synthesis for the molecule mixture for possessing these characteristics, it was demonstrated that it has efficiency and the life for meeting medicine law regulation
Object safety, and this synthesis is transferred to clinical setting will be very expensive process (in fact, available routine treatment
Based on single substance).
For in the self compound of regenerative medicine, being rich in the blood plasma (Platelet-Rich-Plasma, PRP) of blood platelet
Compound is more well-known.PRP compounds are derived from blood samples of patients, are applied to regenerative medicine, main cause, which is it, has special property
Matter：It repairs molecule, also referred to as the tissue repair factor, can the part release (inside blood platelet).It repairs in molecule, it is known that a kind of
Very famous cell signal, commonly known as " growth factor ".Growth factor include PDGF, TGF-β, IGF-I, HGF,
VEGF, EGF and bFGF, it is common to coordinate to act on injury tissue cell by the specific receptor in cell membrane.Growth factor
Interaction between cell is most important in determining cell activity.These growth factors may or may not can trigger
Silk division changes self-generation, changes extracellular matrix synthesis and tissue remodeling, and all these regenerated with injury tissue
Relevant process.
In general, obtaining PRP compounds from following preparation methods comprising four basic steps：Extract blood samples of patients；By blood
Liquid is divided into different piece；The part (platelet-rich part, PRP) rich in blood platelet is isolated from different piece；With
The PRP condenses and (also known as activates) to discharge reparation molecule.As a result, obtaining that there is special consistency (to depend on condensation journey
Degree) and bioactivity PRP compounds.These steps known in the art can carry out configuration and reality with many distinct methods
Apply, thus cause PRP compounds it is qualitative and quantitative composition also there were significant differences.For example, certain known PRP compounds are to be rich in
The blood plasma of blood platelet and leucocyte, and other known PRP compounds are then rich in blood platelet, the blood plasma without leucocyte.It is white thin
Born of the same parents' missing, which may make, reaches a series of beneficial effects.Primary, the repeatability for preparing these compounds is increased, is also provided
Have the PRP compounds of distinguished good biological characteristic.For example, one of the good biological characteristic, is scarce
Lose certain leucocytes for being referred to as " neutrophil cell ".This cell accounts for the 60-70% of whole leucocytes, it is generally recognized that repairing
Tissue in multiple is harmful, because they are the sources of free radical (meeting indifference destroys local cells), and one kind is known as " metal
The source of the enzyme of protease " (especially MMP-8 and MMP-9, the component of extracellular matrix can be destroyed).
PRGF compounds are a kind of PRP compounds for being applied to regenerative medicine.PRGF is containing moderate quatity blood platelet, no
PRP compounds containing leucocyte trigger its activation by addition calcium chloride, this causes release to repair molecule.Addition calcium chloride is led
It causes to form the natural polymer for being known as " fibrin " (fibrin).While providing above-mentioned effect, missing leucocyte can increase
Add fibrinous stability, in other words, postpones fibrinous degradation.This is because following facts：Fibrin can
From the effect of elastoser, the elastoser is can to destroy the water of fibrin matrix (accelerating the substrate degradation)
Enzyme is solved, is generated as the result that the leukocyte activation for being referred to as " granulocyte " acts on.
Prior art includes the Different Variation of PRGF compounds, preparation method and its in a variety of medical conditions
Application in (medical situation) and in vitro cell culture technology.Main known patent have US6569204,
ES2180438B2 and ES2221770B2.These patents describe the preparation method of PRGF compounds, and its are being inserted into tooth implantation
Purposes when object or other kinds of false organ in bone tissue regeneration and its as in eye drops purposes in addition its in vitro
Extend the purposes in cell.Verified PRGF compounds are very beneficial in these routinely application.
Disclosed on 09 22nd, 2010, entitled " treatment joint disease or arthralgia, or be beauty or other mesh
Treatment skin method and compound and the compound preparation method ", application No. is in CN200880101622.6
State's invention patent application disclose it is a kind of treat joint disease or arthralgia, or treatment skin method comprising penetrate into or
Using the compound containing at least one blood derivatives matter, which is especially rich in blood
The blood plasma (PRP) of platelet is preferably rich in the blood plasma (PRGF) of growth factor and/or the supernatant of aforementioned any blood plasma.The innovation
Method makes treatment region obtains significantly alleviating even to regenerate.Optionally, by blood derivatives matter and hyaluronic acid (HA) and/or
HA derivative compounds mix, to reach even more beneficial effect.But its shortcoming is that：PRP technologies need to extract patient certainly
Body blood is detached to be injected again, therefore is suffered from hemopathic patient and be not suitable for carrying out PRP technology treatments, such as decrease of platelet, again
Raw aplastic anemia, leukaemia etc..
The present inventor is disclosed on 08 10th, 2016, entitled " human plasma with multiple functions and its preparation side
Method ", application No. is the Chinese invention patent applications of CN201510489743.4 to disclose a kind of human plasma with multiple functions
And preparation method thereof, including universal blood plasma and blood constituent additive；Universal blood plasma be universal fresh frozen blood plasma or
Universal frozen dry blood plasma；Blood constituent additive is selected from albumin, gamma globulin, blood platelet, fibrinogen, coagulation factor
II, labile factor, proconvertin, blood coagulation factor VIII, plasma thromboplastin component, Stuart factor, plasma thromboplastin antecedent, blood coagulation because
Any one or more in sub- XII, factor XIII and prothrombin complex.Advantage is：For needing while supplementing
The patient of blood plasma and at least one blood constituent additive, it is only necessary to input include the blood plasma of correspondence blood constituent additive i.e.
Can, to increase the range used and flexibility, saves patient and transfuse blood the time, also save blood transfusion equipment.
The present inventor is in clinic it was unexpectedly observed that the human plasma with multiple functions of above-mentioned allogeneic is by changing
Into, be used for arthritic treatment, have unexpected curative effect.
Invention content
It is suitble to carry out PRP technology treatments to suffering from hemopathic patient one of the objects of the present invention is to provide a kind of, such as
The composition for treatment of arthritis of decrease of platelet, alpastic anemia, leukaemia etc..
In order to achieve the above object, the present invention is realized by following four technical solution：
Scheme one：
A kind of compound for treatment of arthritis, proportioning are as follows：Blood plasma 5-6 parts by volume, sodium hyaluronate 2-4 parts by volume,
Blood platelet 0.01-0.03 parts by volume；
The proportioning of the blood plasma is as follows：Including universal blood plasma and blood constituent additive；Wherein, the universal blood plasma
For universal fresh frozen blood plasma or universal frozen dry blood plasma；For the universal fresh frozen blood plasma and the universal jelly
Dry plasma is formed by the blood group blood plasma mixed preparing of following volumes part：A type blood plasma：5-10 parts by volume；Type B blood plasma：2-7 volumes
Part；O-shaped blood plasma：0.5-3 parts by volume；AB type blood plasma：0.5-3 parts by volume；
The blood constituent additive be selected from albumin, gamma globulin, blood platelet, fibrinogen, prothrombin,
Labile factor, proconvertin, blood coagulation factor VIII, plasma thromboplastin component, Stuart factor, plasma thromboplastin antecedent, coagulation factor
Any one or more in XII, factor XIII and prothrombin complex.
Scheme two：
A kind of compound for treating degenerative arthritis, proportioning are as follows：Blood plasma 4-6 parts by volume, sodium hyaluronate 1-2 bodies
Product part, ammonia sugar 1-2 parts by volume, chondroitin sulfate 1.0-1.2 parts by volume, blood platelet 0.01-0.03 parts by volume；
The proportioning of the blood plasma is as follows：Including universal blood plasma and blood constituent additive；Wherein, the universal blood plasma
For universal fresh frozen blood plasma or universal frozen dry blood plasma；For the universal fresh frozen blood plasma and the universal jelly
Dry plasma is formed by the blood group blood plasma mixed preparing of following volumes part：A type blood plasma：5-10 parts by volume；Type B blood plasma：2-7 volumes
Part；O-shaped blood plasma：0.5-3 parts by volume；AB type blood plasma：0.5-3 parts by volume；
The blood constituent additive be selected from albumin, gamma globulin, blood platelet, fibrinogen, prothrombin,
Labile factor, proconvertin, blood coagulation factor VIII, plasma thromboplastin component, Stuart factor, plasma thromboplastin antecedent, coagulation factor
Any one or more in XII, factor XIII and prothrombin complex.
Scheme three：
A kind of compound for treating tuberculous arthritis, proportioning are as follows：Blood plasma 4-6 parts by volume, sodium hyaluronate 3-5 bodies
Product part, blood platelet 0.01-0.03 parts by volume, isoniazid 0.2-0.4 parts by volume；Streptomysin 0.2-0.4 parts by volume；Rifampin 0.2-
0.4 parts by volume；
The proportioning of the blood plasma is as follows：Including universal blood plasma and blood constituent additive；Wherein, the universal blood plasma
For universal fresh frozen blood plasma or universal frozen dry blood plasma；For the universal fresh frozen blood plasma and the universal jelly
Dry plasma is formed by the blood group blood plasma mixed preparing of following volumes part：A type blood plasma：5-10 parts by volume；Type B blood plasma：2-7 volumes
Part；O-shaped blood plasma：0.5-3 parts by volume；AB type blood plasma：0.5-3 parts by volume；
The blood constituent additive be selected from albumin, gamma globulin, blood platelet, fibrinogen, prothrombin,
Labile factor, proconvertin, blood coagulation factor VIII, plasma thromboplastin component, Stuart factor, plasma thromboplastin antecedent, coagulation factor
Any one or more in XII, factor XIII and prothrombin complex.
Scheme four：
A kind of compound for treating rheumatic arthritis, proportioning are as follows：Blood plasma 5-7 parts by volume, sodium hyaluronate 1-3 bodies
Product part, blood platelet 0.01-0.03 parts by volume, aspirin 0.2-0.4 parts by volume, Indomethacin 0.2-0.3 parts by volume, prednisone
0.2-0.4 parts by volume, hydroxychloroquine 0.1-0.3 parts by volume, chloroquine 0.2-3 parts by volume；
The proportioning of the blood plasma is as follows：Including universal blood plasma and blood constituent additive；Wherein, the universal blood plasma
For universal fresh frozen blood plasma or universal frozen dry blood plasma；For the universal fresh frozen blood plasma and the universal jelly
Dry plasma is formed by the blood group blood plasma mixed preparing of following volumes part：A type blood plasma：5-10 parts by volume；Type B blood plasma：2-7 volumes
Part；O-shaped blood plasma：0.5-3 parts by volume；AB type blood plasma：0.5-3 parts by volume；
The blood constituent additive be selected from albumin, gamma globulin, blood platelet, fibrinogen, prothrombin,
Labile factor, proconvertin, blood coagulation factor VIII, plasma thromboplastin component, Stuart factor, plasma thromboplastin antecedent, coagulation factor
Any one or more in XII, factor XIII and prothrombin complex.
Another object of the present invention is to provide the preparation methods of the above-mentioned compound for treatment of arthritis.
In order to achieve the above object, the present invention is achieved through the following technical solutions：
A kind of preparation method of compound for treatment of arthritis, its step are as follows：
1, the preparation of universal blood plasma
Universal blood plasma provided in this embodiment is the universal fresh frozen blood plasma of liquid：
The parts by volume of various blood types blood plasma is：
A type blood plasma：5-10 parts by volume；Type B blood plasma：2-7 parts by volume；O-shaped blood plasma：0.5-3 parts by volume；AB type blood plasma：
0.5-3 parts by volume；
Preparation method is：
The qualified blood plasma speed of acquisition is set into -30 DEG C of stored frozens, by above-mentioned capacity ratio by tetra- kinds of blood group blood of A, B, O and AB
Slurry mixing, and after inactivation of virus, appropriate protective agent sucrose and glutathione is added, it is concentrated by ultrafiltration, degerming forms；
2, the preparation of multi-functional human plasma
Step 1 passes directly to step 2 if raw material is universal fresh frozen blood plasma；If raw material is universal
Frozen dry blood plasma is powdered, powdered universal frozen dry blood plasma is diluted to 38-42mg/ml's using lysate first
Plasma lipid, the plasma lipid diluted are universal fresh frozen blood plasma, then go to step 2)；
Step 2 keeps the temperature of universal fresh frozen blood plasma to be in totally-enclosed, sterile pyrogen-free operating environment
20-24 DEG C, meanwhile, so that universal fresh frozen blood plasma is vibrated by setting frequency of oscillation and amplitude, under oscillation, with 10-50L/
The rate of addition of hr is slowly added to one or more blood constituent additives into universal fresh frozen blood plasma；It is prepared into
To multi-functional human plasma；
3, the preparation for the compound for the treatment of of arthritis
One：
(1) it matches
Multi-functional human plasma 5-6 parts by volume；
Sodium hyaluronate 2-4 parts by volume；
Blood platelet 0.01-0.03 parts by volume；
(2) preparation process
In totally-enclosed, sterile pyrogen-free operating environment, it is 20-24 DEG C to keep the temperature of multi-functional human plasma, meanwhile,
Multi-functional human plasma is set to vibrate by setting frequency of oscillation and amplitude, under being vibrated at 5-10 beats/min, with the dropwise addition of 200ml/min
Speed is slowly added to sodium hyaluronate, the blood platelet of required content into multi-functional human plasma successively, that is, allogeneic is prepared and controls
Treat arthritic compound.
Secondly：
(1) it matches
(2) preparation process
In totally-enclosed, sterile pyrogen-free operating environment, it is 20-24 DEG C to keep the temperature of multi-functional human plasma, meanwhile,
Multi-functional human plasma is set to vibrate by setting frequency of oscillation and amplitude, under being vibrated at 5-10 beats/min, with the dropwise addition of 200ml/min
Speed is slowly added to sodium hyaluronate, ammonia sugar, chondroitin sulfate, the blood platelet of required content into multi-functional human plasma, that is, makes successively
It is standby to obtain the compound of allogeneic treatment degenerative arthritis.
Thirdly：
(1) it matches
(2) preparation process
In totally-enclosed, sterile pyrogen-free operating environment, it is 20-24 DEG C to keep the temperature of multi-functional human plasma, meanwhile,
Multi-functional human plasma is set to vibrate by setting frequency of oscillation and amplitude, under being vibrated at 5-10 beats/min, with the dropwise addition of 200ml/min
Speed is slowly added to sodium hyaluronate, ammonia sugar, chondroitin sulfate, blood platelet, the different cigarette of required content into multi-functional human plasma successively
The compound of allogeneic treatment tuberculous arthritis is prepared in hydrazine, streptomysin, rifampin.
It four：
(1) it matches
(2) preparation process
In totally-enclosed, sterile pyrogen-free operating environment, it is 20-24 DEG C to keep the temperature of multi-functional human plasma, meanwhile,
Multi-functional human plasma is set to vibrate by setting frequency of oscillation and amplitude, under being vibrated at 5-10 beats/min, with the dropwise addition of 200ml/min
Speed is slowly added to the sodium hyaluronate of required content into multi-functional human plasma, blood platelet, aspirin, Indomethacin, sprinkles successively
The compound of allogeneic treatment rheumatic arthritis is prepared in Buddhist nun pine, hydroxychloroquine, chloroquine.
Wherein, the preservation condition of the multi-functional human plasma prepared in the step 2 is：At a temperature of 20-24 DEG C, press institute
It states setting frequency of oscillation and amplitude oscillatory preserves multi-functional human plasma.
Preferably, powdered universal frozen dry blood plasma is diluted to the plasma lipid of 38-42mg/ml using lysate
In the process, used lysate is the citron acid injection of sterile, apyrogeneity matter 0.1%g/ml, also, citric acid is injected
The pH value of liquid is 2.6~3.0；Alternatively, used lysate is sterilized water for injection, which includes 5% Portugal
Grape sugar injection.
Preferably, it is described set frequency of oscillation as：5-10 beats/min；The amplitude is：5-10 millimeters.
Advantages of the present invention：
Existing PRP technologies, which need to extract patient's self-blood, to be detached and is injected again, therefore suffers from hemopathic patient not
It is appropriate for the treatment of PRP technologies, such as decrease of platelet, alpastic anemia, leukaemia.For decrease of platelet, white blood
Patient and other arthritic patients, the human plasma of present patent application can then be applied, can be according to blood testing knot
Fruit and joint fluid result of laboratory test input computer model are matched, and are then allocated in vitro, are injected into human synovial intracavitary.
It needs to be emphasized that these are not the ranges of this field conventional selection, are not those skilled in the art's energy
That enough makes is typically chosen.
With reference to specific embodiment, the present invention will be further described, but is not meant to the scope of the present invention
Limitation.
Specific implementation mode：
Embodiment 1：The preparation of the compound for the treatment of of arthritis
1, the preparation of universal blood plasma
Universal blood plasma provided in this embodiment is the universal fresh frozen blood plasma of liquid：
The parts by volume of various blood types blood plasma is：
A type blood plasma：5 parts by volume；Type B blood plasma：2 parts by volume；O-shaped blood plasma：2 parts by volume；AB type blood plasma：1 parts by volume；
Preparation method is：
The qualified blood plasma speed of acquisition is set into -30 DEG C of stored frozens, by above-mentioned capacity ratio by tetra- kinds of blood group blood of A, B, O and AB
Slurry mixing, and after inactivation of virus, appropriate protective agent sucrose and glutathione is added, it is concentrated by ultrafiltration, degerming forms.
2, the preparation of multi-functional human plasma
The universal fresh frozen blood plasma 10ml that step 1 is prepared is taken, in totally-enclosed, sterile pyrogen-free operating environment
In, it is 20-24 DEG C to keep the temperature of universal fresh frozen blood plasma, meanwhile, by 5 beats/min of frequency of oscillation, 5 millimeters of amplitudes
So that universal fresh frozen blood plasma is vibrated, under oscillation, with the rate of addition of 50L/hr, delays into universal fresh frozen blood plasma
It is slow that albumin blood component additive 1000mg is added；After blood component additive is added, multi-functional people is prepared
Blood plasma 15ml.
3, for the compound for the treatment of of arthritis with when preparation process
(1) it matches
5 milliliters of multi-functional human plasma prepared by step 2；
2 milliliters of sodium hyaluronate；
0.02 milliliter of blood platelet；
(2) preparation process
In totally-enclosed, sterile pyrogen-free operating environment, the temperature of multi-functional human plasma prepared by holding step 2 is
20-24 DEG C, meanwhile, so that multi-functional human plasma is vibrated by setting frequency of oscillation and amplitude, under being vibrated at 5-10 beats/min, with
The rate of addition of 200ml/min is slowly added to sodium hyaluronate, the blood platelet of required content into multi-functional human plasma, that is, makes successively
It is standby to obtain the compound 1 of allogeneic treatment of arthritis.
4, with existing platelet rich plasma (PRP) Technical comparing
Although the indication of existing platelet rich plasma technology, than wide, patient not used can be carried out this
Treatment.It is injected again since technique needs to detach autoblood cell, the patient with hematologic disease is uncomfortable
It closes and carries out platelet rich plasma treatment, such as thrombopenia, the hematologic diseases such as leukaemia.And the allogeneic treatment of the present invention
Arthritic compound is aided with other components, solves this technical barrier, can give due to adding multi-functional human plasma
Patient with hematologic disease carries out arthritic treatment.
Embodiment 2：The preparation of the compound for the treatment of of arthritis
1, prepared by universal blood plasma
Universal blood plasma provided in this embodiment is the universal fresh frozen blood plasma of liquid：
The parts by volume of various blood types blood plasma is：
A type blood plasma：5 parts by volume；Type B blood plasma：3 parts by volume；O-shaped blood plasma：1 parts by volume；AB type blood plasma：1 parts by volume；
Preparation method is：
The qualified blood plasma speed of acquisition is set into -30 DEG C of stored frozens, by above-mentioned capacity ratio by tetra- kinds of blood group blood of A, B, O and AB
Slurry mixing, and after inactivation of virus, appropriate protective agent sweet dew alcohol and glucose is added, it is concentrated by ultrafiltration, degerming forms.
2, the preparation of multi-functional human plasma
The universal fresh frozen blood plasma 10ml that step 1 is prepared is taken, in totally-enclosed, sterile pyrogen-free operating environment
In, it is 20-24 DEG C to keep the temperature of universal fresh frozen blood plasma, meanwhile, it shakes by 10 beats/min of frequency of oscillation, 10 millimeters
Width makes universal fresh frozen blood plasma vibrate, under oscillation, with the rate of addition of 30L/hr, into universal fresh frozen blood plasma
It is slowly added to 3,000,000, blood platelet and fibrinogen 100mg；After blood component additive is added, it is prepared more
Function human plasma 15ml.
3, for the compound for the treatment of of arthritis with when preparation process
(1) it matches
6 milliliters of blood plasma prepared by step 2；
3 milliliters of sodium hyaluronate；
0.02 milliliter of blood platelet；
(2) preparation process
In totally-enclosed, sterile pyrogen-free operating environment, the temperature of multi-functional human plasma prepared by holding step 2 is
20-24 DEG C, meanwhile, so that multi-functional human plasma is vibrated by setting frequency of oscillation and amplitude, under being vibrated at 5-10 beats/min, with
The rate of addition of 200ml/min is slowly added to sodium hyaluronate, the blood platelet of required content into multi-functional human plasma, that is, makes successively
It is standby to obtain the compound 2 of allogeneic treatment of arthritis.
Embodiment 3：It is prepared by the compound for the treatment of of arthritis
1, prepared by universal blood plasma
Universal blood plasma provided in this embodiment is the universal fresh frozen blood plasma of liquid：
The parts by volume of various blood types blood plasma is：
A type blood plasma：6 parts by volume；Type B blood plasma：3 parts by volume；O-shaped blood plasma：0.5 parts by volume；AB type blood plasma：0.5 parts by volume；
Preparation method is：
The qualified blood plasma speed of acquisition is set into -30 DEG C of stored frozens, by above-mentioned capacity ratio by tetra- kinds of blood group blood of A, B, O and AB
Slurry mixing, and after inactivation of virus, appropriate protective agent calcium chloride is added, it is concentrated by ultrafiltration, degerming forms.
2, the preparation of multi-functional human plasma
The universal fresh frozen blood plasma 10ml that step 1 is prepared is taken, in totally-enclosed, sterile pyrogen-free operating environment
In, it is 20-24 DEG C to keep the temperature of universal fresh frozen blood plasma, meanwhile, by 8 beats/min of frequency of oscillation, 7 millimeters of amplitudes
So that universal fresh frozen blood plasma is vibrated, under oscillation, with the rate of addition of 20L/hr, delays into universal fresh frozen blood plasma
It is slow that prothrombin 0.1mg is added, labile factor 10mg, blood coagulation factors IX-10 .03mg, plasma thromboplastin antecedent 0.005mg, coagulates
Blood factor XIII 2mg and gamma globulin 30mg；After blood component additive is added, that is, multi-functional people is prepared
Blood plasma 15ml.
3, for the compound for the treatment of of arthritis with when preparation process
(1) it matches
5 milliliters of multi-functional human plasma prepared by step 2；
4 milliliters of sodium hyaluronate；
0.02 milliliter of blood platelet；
(2) preparation process
In totally-enclosed, sterile pyrogen-free operating environment, the temperature of multi-functional human plasma prepared by holding step 2 is
20-24 DEG C, meanwhile, so that multi-functional human plasma is vibrated by setting frequency of oscillation and amplitude, under being vibrated at 5-10 beats/min, with
The rate of addition of 200ml/min is slowly added to sodium hyaluronate, the blood platelet of required content into multi-functional human plasma, that is, makes successively
It is standby to obtain the compound 3 of allogeneic treatment of arthritis.
Embodiment 4：It is prepared by the compound for treating degenerative arthritis
1, prepared by universal blood plasma
Universal blood plasma provided in this embodiment is the universal fresh frozen blood plasma of liquid：
The parts by volume of various blood types blood plasma is：
A type blood plasma：5 parts by volume；Type B blood plasma：3.5 parts by volume；O-shaped blood plasma：0.5 parts by volume；AB type blood plasma：1.0 volume
Part；
Preparation method is：
The qualified blood plasma speed of acquisition is set into -30 DEG C of stored frozens, by above-mentioned capacity ratio by tetra- kinds of blood group blood of A, B, O and AB
Slurry mixing, and after inactivation of virus, appropriate protective agent calcium chloride is added, it is concentrated by ultrafiltration, degerming forms.
2, the preparation of multi-functional human plasma
The universal fresh frozen blood plasma 10ml that step 1 is prepared is taken, in totally-enclosed, sterile pyrogen-free operating environment
In, it is 20-24 DEG C to keep the temperature of universal fresh frozen blood plasma, meanwhile, by 6 beats/min of frequency of oscillation, 7 millimeters of amplitudes
So that universal fresh frozen blood plasma is vibrated, under oscillation, with the rate of addition of 40L/hr, delays into universal fresh frozen blood plasma
It is slow that prothrombin complex 0.184g and albumin 4500mg is added；After blood component additive is added, it is prepared
Multi-functional human plasma 20ml.
3, for treat degenerative arthritis compound with when preparation process
(1) it matches
(2) preparation process
In totally-enclosed, sterile pyrogen-free operating environment, the temperature of multi-functional human plasma prepared by holding step 2 is
20-24 DEG C, meanwhile, so that multi-functional human plasma is vibrated by setting frequency of oscillation and amplitude, under being vibrated at 5-10 beats/min, with
The rate of addition of 200ml/min, the sodium hyaluronate, ammonia sugar, sulfuric acid for being slowly added to required content successively into multi-functional human plasma are soft
The compound 1 of allogeneic treatment degenerative arthritis is prepared in ossein, blood platelet.
4, with existing platelet rich plasma (PRP) Technical comparing
Although the indication of existing platelet rich plasma technology, than wide, patient not used can be carried out this
Treatment.It is injected again since technique needs to detach autoblood cell, the patient with hematologic disease is uncomfortable
It closes and carries out platelet rich plasma treatment, such as thrombopenia, the hematologic diseases such as leukaemia.And the allogeneic treatment of the present invention
Arthritic compound solves this problem, can give the patient with hematologic disease due to adding multi-functional human plasma
Carry out arthritic treatment.
Embodiment 5：Treat the preparation of the compound of degenerative arthritis
1, prepared by universal blood plasma
Universal blood plasma provided in this embodiment is the universal frozen dry blood plasma of pulverulence：
The parts by volume of various blood types blood plasma is：
A type blood plasma：5 parts by volume；Type B blood plasma：2 parts by volume；O-shaped blood plasma：2 parts by volume；AB type blood plasma：1 parts by volume；
Preparation method is：
The qualified blood plasma speed of acquisition is set into -30 DEG C of stored frozens, by above-mentioned capacity ratio by tetra- kinds of blood group blood of A, B, O and AB
Slurry mixing, and after inactivation of virus, appropriate protective agent calcium chloride and sucrose is added, degerming dispenses, then at a temperature of≤- 30 DEG C
Rotation jelly is carried out, then frozen dried at a temperature of≤35 DEG C and in≤50 hours, obtains universal frozen dry blood plasma preparation.
2, the preparation of multi-functional human plasma
It is raw material to take the universal frozen dry blood plasma preparation that step 1 is prepared, in totally-enclosed, sterile pyrogen-free operation ring
In border, the plasma lipid of 45mg/ml is diluted to using lysate, it is 20-24 DEG C to keep the temperature of plasma lipid, meanwhile,
Plasma lipid is set to vibrate by 6 beats/min of frequency of oscillation, 7 millimeters of amplitudes, under oscillation, in terms of the plasma lipid of 10ml, with
The rate of addition of 10-50L/hr is slowly added to the blood constituent additive of following proportioning into plasma lipid：
After blood component additive is added, multi-functional human plasma 14.55ml is prepared.
That 3, treats the compound of degenerative arthritis matches when preparation process
(1) it matches
(2) preparation process
In totally-enclosed, sterile pyrogen-free operating environment, the temperature of multi-functional human plasma prepared by holding step 2 is
20-24 DEG C, meanwhile, so that multi-functional human plasma is vibrated by setting frequency of oscillation and amplitude, under being vibrated at 5-10 beats/min, with
The rate of addition of 200ml/min, the sodium hyaluronate, ammonia sugar, sulfuric acid for being slowly added to required content successively into multi-functional human plasma are soft
The compound 2 of allogeneic treatment degenerative arthritis is prepared in ossein, blood platelet.
4, the application of the compound for the treatment of degenerative arthritis
The compound for treating degenerative arthritis includes mainly high concentration blood platelet and treats the drug of arthralgia damage
It constitutes, blood platelet also has prior effect rich in the raised growth factor in self healing of human body and repair process, it is people
Blood platelet rich in the raised growth factor is injected into patient's body, to cell in joint tissue and matrix by " crude drug again " of body
Regeneration play facilitation, to accelerate the reparation of joint tissue.It can be used for treating common scapulohumeral periarthritis, gonitis, tough
The treatments such as band damage, myotenositis, tenosynovitis.
Embodiment 6：Treat the preparation of the compound of degenerative arthritis
1, prepared by universal blood plasma
Universal blood plasma provided in this embodiment is the universal frozen dry blood plasma of pulverulence：
The parts by volume of various blood types blood plasma is：
A type blood plasma：5 parts by volume；Type B blood plasma：3 parts by volume；O-shaped blood plasma：1 parts by volume；AB type blood plasma：1 parts by volume；
Preparation method is：
The qualified blood plasma speed of acquisition is set into -30 DEG C of stored frozens, by above-mentioned capacity ratio by tetra- kinds of blood group blood of A, B, O and AB
Slurry mixing, and after inactivation of virus, appropriate protective agent mannitol, glucose and glutathione is added, degerming dispenses, then≤-
Rotation jelly is carried out at a temperature of 30 DEG C, then frozen dried at a temperature of≤35 DEG C and in≤50 hours, obtains universal freeze-drying
Blood plasma preparation.
2, the preparation of multi-functional human plasma
It is raw material to take the universal frozen dry blood plasma preparation that step 1 is prepared, in totally-enclosed, sterile pyrogen-free operation ring
In border, the plasma lipid of 45mg/ml is diluted to using lysate, it is 20-24 DEG C to keep the temperature of plasma lipid, meanwhile,
Plasma lipid is set to vibrate by 7 beats/min of frequency of oscillation, 8 millimeters of amplitudes, under oscillation, in terms of the plasma lipid of 10ml, with
The rate of addition of 10-50L/hr is slowly added to the blood constituent additive of following proportioning into plasma lipid：
After blood component additive is added, multi-functional human plasma 15.15ml is prepared.
That 3, treats the compound of degenerative arthritis matches when preparation process
(1) it matches
(2) preparation process
In totally-enclosed, sterile pyrogen-free operating environment, the temperature of multi-functional human plasma prepared by holding step 2 is
20-24 DEG C, meanwhile, so that multi-functional human plasma is vibrated by setting frequency of oscillation and amplitude, under being vibrated at 5-10 beats/min, with
The rate of addition of 200ml/min, the sodium hyaluronate, ammonia sugar, sulfuric acid for being slowly added to required content successively into multi-functional human plasma are soft
The compound 3 of allogeneic treatment degenerative arthritis is prepared in ossein, blood platelet.
Embodiment 7：Treat the preparation of the compound of tuberculous arthritis
1, prepared by universal blood plasma
Universal blood plasma provided in this embodiment is the universal frozen dry blood plasma of pulverulence：
The parts by volume of various blood types blood plasma is：
A type blood plasma：6 parts by volume；Type B blood plasma：3 parts by volume；O-shaped blood plasma：0.5 parts by volume；AB type blood plasma：0.5 parts by volume；
Preparation method is：
The qualified blood plasma speed of acquisition is set into -30 DEG C of stored frozens, by above-mentioned capacity ratio by tetra- kinds of blood group blood of A, B, O and AB
Slurry mixing, and after inactivation of virus, appropriate protective agent sucrose, sweet dew alcohol and glucose is added, degerming dispenses, then at≤- 30 DEG C
At a temperature of carry out rotation jelly, then at a temperature of≤35 DEG C and≤50 hours in frozen dried, obtain universal frozen dry blood plasma
Preparation.
2, the preparation of multi-functional human plasma
It is raw material to take the universal frozen dry blood plasma preparation that step 1 is prepared, in totally-enclosed, sterile pyrogen-free operation ring
In border, the plasma lipid of 38mg/ml is diluted to using lysate, it is 20-24 DEG C to keep the temperature of plasma lipid, meanwhile,
Plasma lipid is set to vibrate by 6 beats/min of frequency of oscillation, 7 millimeters of amplitudes, under oscillation, in terms of the plasma lipid of 10ml, with
The rate of addition of 10-50L/hr is slowly added to the blood constituent additive of following proportioning into plasma lipid：
After blood component additive is added, multi-functional human plasma 13.83ml is prepared.
That 3, treats the compound of tuberculous arthritis matches when preparation process
(1) it matches
(2) preparation process
In totally-enclosed, sterile pyrogen-free operating environment, the temperature of multi-functional human plasma prepared by holding step 2 is
20-24 DEG C, meanwhile, so that multi-functional human plasma is vibrated by setting frequency of oscillation and amplitude, under being vibrated at 5-10 beats/min, with
The rate of addition of 200ml/min is slowly added to the sodium hyaluronate, blood platelet, different cigarette of required content into multi-functional human plasma successively
The compound 1 of allogeneic treatment tuberculous arthritis is prepared in hydrazine, streptomysin, rifampin.
4, with existing platelet rich plasma (PRP) Technical comparing
Although the indication of existing platelet rich plasma technology, than wide, patient not used can be carried out this
Treatment.It is injected again since technique needs to detach autoblood cell, the patient with hematologic disease is uncomfortable
It closes and carries out platelet rich plasma treatment, such as thrombopenia, the hematologic diseases such as leukaemia.And the allogeneic treatment of the present invention
The compound of tuberculous arthritis solves this technical barrier, can give and suffer from blood due to adding multi-functional human plasma
The patient of disease carries out arthritic treatment.
Embodiment 8：Treat the preparation of the compound of rheumatic arthritis
1, prepared by universal blood plasma
Universal blood plasma provided in this embodiment is the universal frozen dry blood plasma of pulverulence：
The parts by volume of various blood types blood plasma is：
A type blood plasma：5 parts by volume；Type B blood plasma：3.5 parts by volume；O-shaped blood plasma：0.5 parts by volume；AB type blood plasma：1.0 volume
Part；
Preparation method is：
The qualified blood plasma speed of acquisition is set into -30 DEG C of stored frozens, by above-mentioned capacity ratio by tetra- kinds of blood group blood of A, B, O and AB
Slurry mixing, and after inactivation of virus, appropriate protective agent sucrose and glucose is added, degerming dispenses, then at a temperature of≤- 30 DEG C
Rotation jelly is carried out, then frozen dried at a temperature of≤35 DEG C and in≤50 hours, obtains universal frozen dry blood plasma preparation.
2, the preparation of multi-functional human plasma
It is raw material to take the universal frozen dry blood plasma preparation that step 1 is prepared, in totally-enclosed, sterile pyrogen-free operation ring
In border, the plasma lipid of 42mg/ml is diluted to using lysate, it is 20-24 DEG C to keep the temperature of plasma lipid, meanwhile,
Plasma lipid is set to vibrate by 6 beats/min of frequency of oscillation, 7 millimeters of amplitudes, under oscillation, in terms of the plasma lipid of 10ml, with
The rate of addition of 10-50L/hr is slowly added to the blood constituent additive of following proportioning into plasma lipid：
After blood component additive is added, multi-functional human plasma 13.13ml is prepared；
That 3, treats the compound of rheumatic arthritis matches when preparation process
(1) it matches
(2) preparation process
In totally-enclosed, sterile pyrogen-free operating environment, the temperature of multi-functional human plasma prepared by holding step 2 is
20-24 DEG C, meanwhile, so that multi-functional human plasma is vibrated by setting frequency of oscillation and amplitude, under being vibrated at 5-10 beats/min, with
The rate of addition of 200ml/min is slowly added to the sodium hyaluronate, blood platelet, A Si of required content into multi-functional human plasma successively
The compound 1 of allogeneic treatment rheumatic arthritis is prepared in woods, Indomethacin, prednisone, hydroxychloroquine, chloroquine.
4, with existing platelet rich plasma (PRP) Technical comparing
Although the indication of existing platelet rich plasma technology, than wide, patient not used can be carried out this
Treatment.It is injected again since technique needs to detach autoblood cell, the patient with hematologic disease is uncomfortable
It closes and carries out platelet rich plasma treatment, such as thrombopenia, the hematologic diseases such as leukaemia.And the allogeneic treatment of the present invention
The compound of rheumatic arthritis solves this technical barrier, can give and suffer from blood due to adding multi-functional human plasma
The patient of disease carries out arthritic treatment.
Claims (7)
1. a kind of compound for treatment of arthritis, proportioning is as follows：Blood plasma 5-6 parts by volume, sodium hyaluronate 2-4 parts by volume, blood
Platelet 0.01-0.03 parts by volume；
The proportioning of the blood plasma is as follows：Including universal blood plasma and blood constituent additive；Wherein, the universal blood plasma is logical
With type fresh frozen plasma or universal frozen dry blood plasma；For the universal fresh frozen blood plasma and the universal freeze-drying blood
Slurry, is formed by the blood group blood plasma mixed preparing of following volumes part：A type blood plasma：5-10 parts by volume；Type B blood plasma：2-7 parts by volume；O
Type blood plasma：0.5-3 parts by volume；AB type blood plasma：0.5-3 parts by volume；
The blood constituent additive is selected from albumin, gamma globulin, blood platelet, fibrinogen, prothrombin, blood coagulation
Factor Ⅴ, blood coagulation factor VIII, plasma thromboplastin component, Stuart factor, plasma thromboplastin antecedent, Hageman factor, coagulates at proconvertin
Any one or more in blood factor XIII and prothrombin complex.
2. a kind of compound for treating degenerative arthritis, proportioning is as follows：Blood plasma 4-6 parts by volume, sodium hyaluronate 1-2 volumes
Part, ammonia sugar 1-2 parts by volume, chondroitin sulfate 1.0-1.2 parts by volume, blood platelet 0.01-0.03 parts by volume；
The proportioning of the blood plasma is as follows：Including universal blood plasma and blood constituent additive；Wherein, the universal blood plasma is logical
With type fresh frozen plasma or universal frozen dry blood plasma；For the universal fresh frozen blood plasma and the universal freeze-drying blood
Slurry, is formed by the blood group blood plasma mixed preparing of following volumes part：A type blood plasma：5-10 parts by volume；Type B blood plasma：2-7 parts by volume；O
Type blood plasma：0.5-3 parts by volume；AB type blood plasma：0.5-3 parts by volume；
The blood constituent additive is selected from albumin, gamma globulin, blood platelet, fibrinogen, prothrombin, blood coagulation
Factor Ⅴ, blood coagulation factor VIII, plasma thromboplastin component, Stuart factor, plasma thromboplastin antecedent, Hageman factor, coagulates at proconvertin
Any one or more in blood factor XIII and prothrombin complex.
3. a kind of compound for treating tuberculous arthritis, proportioning is as follows：Blood plasma 4-6 parts by volume, sodium hyaluronate 3-5 volumes
Part, blood platelet 0.01-0.03 parts by volume, isoniazid 0.2-0.4 parts by volume；Streptomysin 0.2-0.4 parts by volume；Rifampin 0.2-
0.4 parts by volume；
The proportioning of the blood plasma is as follows：Including universal blood plasma and blood constituent additive；Wherein, the universal blood plasma is logical
With type fresh frozen plasma or universal frozen dry blood plasma；For the universal fresh frozen blood plasma and the universal freeze-drying blood
Slurry, is formed by the blood group blood plasma mixed preparing of following volumes part：A type blood plasma：5-10 parts by volume；Type B blood plasma：2-7 parts by volume；O
Type blood plasma：0.5-3 parts by volume；AB type blood plasma：0.5-3 parts by volume；
The blood constituent additive is selected from albumin, gamma globulin, blood platelet, fibrinogen, prothrombin, blood coagulation
Factor Ⅴ, blood coagulation factor VIII, plasma thromboplastin component, Stuart factor, plasma thromboplastin antecedent, Hageman factor, coagulates at proconvertin
Any one or more in blood factor XIII and prothrombin complex.
4. a kind of compound for treating rheumatic arthritis, proportioning is as follows：Blood plasma 5-7 parts by volume, sodium hyaluronate 1-3 volumes
Part, blood platelet 0.01-0.03 parts by volume, aspirin 0.2-0.4 parts by volume, Indomethacin 0.2-0.3 parts by volume, prednisone
0.2-0.4 parts by volume, hydroxychloroquine 0.1-0.3 parts by volume；
The proportioning of the blood plasma is as follows：Including universal blood plasma and blood constituent additive；Wherein, the universal blood plasma is logical
With type fresh frozen plasma or universal frozen dry blood plasma；For the universal fresh frozen blood plasma and the universal freeze-drying blood
Slurry, is formed by the blood group blood plasma mixed preparing of following volumes part：A type blood plasma：5-10 parts by volume；Type B blood plasma：2-7 parts by volume；O
Type blood plasma：0.5-3 parts by volume；AB type blood plasma：0.5-3 parts by volume；
The blood constituent additive is selected from albumin, gamma globulin, blood platelet, fibrinogen, prothrombin, blood coagulation
Factor Ⅴ, blood coagulation factor VIII, plasma thromboplastin component, Stuart factor, plasma thromboplastin antecedent, Hageman factor, coagulates at proconvertin
Any one or more in blood factor XIII and prothrombin complex.
5. a kind of preparation method of compound for treatment of arthritis, its step are as follows：
(1) preparation of universal blood plasma
The parts by volume of various blood types blood plasma is：
A type blood plasma：5-10 parts by volume；Type B blood plasma：2-7 parts by volume；O-shaped blood plasma：0.5-3 parts by volume；AB type blood plasma：0.5-3 bodies
Product part；
Preparation method is：
The qualified blood plasma speed of acquisition is set into -30 DEG C of stored frozens, mixes tetra- kinds of blood group blood plasma of A, B, O and AB by above-mentioned capacity ratio
It closes, and after inactivation of virus, appropriate protective agent sucrose and glutathione is added, be concentrated by ultrafiltration, degerming forms；
(2) preparation of multi-functional human plasma sum
1), if raw material is universal fresh frozen blood plasma, step 2) is passed directly to；If raw material is universal freeze-drying blood
Slurry is powdered, uses lysate that powdered universal frozen dry blood plasma is diluted to the blood plasma liquid of 38-42mg/ml first
Body, the plasma lipid diluted are universal fresh frozen blood plasma, then go to step 2)；
2), in totally-enclosed, sterile pyrogen-free operating environment, it is 20-24 DEG C to keep the temperature of universal fresh frozen blood plasma,
Meanwhile so that universal fresh frozen blood plasma is vibrated by setting frequency of oscillation and amplitude, under oscillation, with the dropwise addition of 10-50L/hr
Speed is slowly added to one or more blood constituent additives into universal fresh frozen blood plasma；It is prepared multi-functional
Human plasma；
(3) be used for the compound for the treatment of of arthritis has following four kinds with when preparation process：
One：
● proportioning
Multi-functional human plasma 5-6 parts by volume；
Sodium hyaluronate 2-4 parts by volume；
Blood platelet 0.01-0.03 parts by volume；
● preparation process
In totally-enclosed, sterile pyrogen-free operating environment, it is 20-24 DEG C to keep the temperature of multi-functional human plasma, meanwhile, by setting
Determine frequency of oscillation and amplitude makes multi-functional human plasma vibrate, under being vibrated at 5-10 beats/min, with the rate of addition of 200ml/min,
It is slowly added to sodium hyaluronate, the blood platelet of required content successively into multi-functional human plasma, that is, allogeneic treatment is prepared and closes
Save scorching compound；
Secondly：
● proportioning
● preparation process
In totally-enclosed, sterile pyrogen-free operating environment, it is 20-24 DEG C to keep the temperature of multi-functional human plasma, meanwhile, by setting
Determine frequency of oscillation and amplitude makes multi-functional human plasma vibrate, under being vibrated at 5-10 beats/min, with the rate of addition of 200ml/min,
It is slowly added to sodium hyaluronate, ammonia sugar, chondroitin sulfate, the blood platelet of required content successively into multi-functional human plasma, is prepared
The compound of allogeneic treatment of arthritis；
Thirdly：
● proportioning
● preparation process
In totally-enclosed, sterile pyrogen-free operating environment, it is 20-24 DEG C to keep the temperature of multi-functional human plasma, meanwhile, by setting
Determine frequency of oscillation and amplitude makes multi-functional human plasma vibrate, under being vibrated at 5-10 beats/min, with the rate of addition of 200ml/min,
It is slowly added to sodium hyaluronate, ammonia sugar, chondroitin sulfate, blood platelet, isoniazid, the chain of required content successively into multi-functional human plasma
The compound of allogeneic treatment of arthritis is prepared in mycin, rifampin；
It four：
● proportioning
● preparation process
In totally-enclosed, sterile pyrogen-free operating environment, it is 20-24 DEG C to keep the temperature of multi-functional human plasma, meanwhile, by setting
Determine frequency of oscillation and amplitude makes multi-functional human plasma vibrate, under being vibrated at 5-10 beats/min, with the rate of addition of 200ml/min,
Be slowly added to successively into multi-functional human plasma the sodium hyaluronate of required content, blood platelet, aspirin, Indomethacin, prednisone,
The compound of allogeneic treatment of arthritis is prepared in hydroxychloroquine, chloroquine；
Wherein, the preservation condition of the multi-functional human plasma of preparation is in the step 2)：At a temperature of 20-24 DEG C, by described
It sets frequency of oscillation and amplitude oscillatory preserves multi-functional human plasma.
6. the preparation method of the compound according to claim 5 for treatment of arthritis, it is characterised in that：The step
1) during the plasma lipid that powdered universal frozen dry blood plasma is diluted to described in using lysate 38-42mg/ml,
Used lysate is the citron acid injection of sterile, apyrogeneity matter 0.1%g/ml, also, the pH of citron acid injection
Value is 2.6~3.0；Alternatively, used lysate is sterilized water for injection, which notes including 5% glucose
Penetrate liquid.
7. the preparation method of the compound according to claim 5 for treatment of arthritis, it is characterised in that：The setting
Frequency of oscillation is：5-10 beats/min；The amplitude is：5-10 millimeters.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810200703.7A CN108310013A (en) | 2018-03-12 | 2018-03-12 | A kind of compound and preparation method thereof for treatment of arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810200703.7A CN108310013A (en) | 2018-03-12 | 2018-03-12 | A kind of compound and preparation method thereof for treatment of arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108310013A true CN108310013A (en) | 2018-07-24 |
Family
ID=62900741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810200703.7A Pending CN108310013A (en) | 2018-03-12 | 2018-03-12 | A kind of compound and preparation method thereof for treatment of arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108310013A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101842104A (en) * | 2007-08-02 | 2010-09-22 | 生物技术研究所I+D有限公司 | Treatment joint disease or arthralgia perhaps are the method and the chemical compound of beauty treatment or other therapeutic interest skins, and the preparation method of this chemical compound |
| CN104707141A (en) * | 2013-12-13 | 2015-06-17 | 星耀控股有限公司 | Composition for treating osteoarthritis |
| CN105832768A (en) * | 2015-08-11 | 2016-08-10 | 杜祖英 | Human plasma with multiple functions and preparation method thereof |
-
2018
- 2018-03-12 CN CN201810200703.7A patent/CN108310013A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101842104A (en) * | 2007-08-02 | 2010-09-22 | 生物技术研究所I+D有限公司 | Treatment joint disease or arthralgia perhaps are the method and the chemical compound of beauty treatment or other therapeutic interest skins, and the preparation method of this chemical compound |
| CN104707141A (en) * | 2013-12-13 | 2015-06-17 | 星耀控股有限公司 | Composition for treating osteoarthritis |
| CN105832768A (en) * | 2015-08-11 | 2016-08-10 | 杜祖英 | Human plasma with multiple functions and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6284987B2 (en) | Virus-inactivated platelet extract, its use and preparation | |
| AU2003221946B2 (en) | Compositions and minimally invasive methods for treating incomplete connective tissue repair | |
| Chao et al. | Infusible platelet membrane microvesicles: a potential transfusion substitute for platelets | |
| JP2010535188A (en) | Methods and compounds for the treatment of joint diseases or joint pain or for the treatment of skin for aesthetic or other purposes and methods for the preparation of compounds | |
| CN104994886B (en) | The biological mixture of inactivation of virus | |
| US10456500B2 (en) | Implantable preparations for regeneration of tissues and treatment of wounds, their method of preparation, and method of treatment of patients with said implantable preparations | |
| EP1890713B1 (en) | Osteoblast composition of semi-solidified mixed fibrin for bone fracture agglutination and its manufacturing method | |
| CN108310013A (en) | A kind of compound and preparation method thereof for treatment of arthritis | |
| JP6877360B2 (en) | Hemostatic composition | |
| CN108492860B (en) | Medicine quantification method of allogeneic platelet-rich plasma wrinkle-removing cosmetic compound based on 3D scanning technology | |
| do Amaral et al. | Platelets in tissue regeneration | |
| JP4679730B2 (en) | Fibrinogen preparation with excellent solubility | |
| CN107693849B (en) | Biological glue for promoting blood vessel reconstruction after cell and organ transplantation and preparation method thereof | |
| US20120308550A1 (en) | Method of Using Fish Plasma Components to Promote Functional Recovery in the Mammialian CNS | |
| JPS6137733A (en) | Drug preparation for hepatic disease | |
| Lanham et al. | Pseudomonas aeruginosa infection with marrow suppression simulating acute promyelocytic leukemia | |
| Burger et al. | Calcification XIX. Calcification of Transplanted Rachitic Bone. | |
| Ivanovska et al. | Principles and methods for isolation and preparation of plasma preparations containing platelets (PR)-how to improve the purpose and effectiveness | |
| RU2323734C2 (en) | Autograft for replacement of bone cavity in treatment of chronic osteomyelitis | |
| Kumar et al. | PLATELET RICH PLASMA. | |
| Agarwal et al. | Evaluation of formalin preserved allogeneic bone graft as a grafting material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180724 |
|
| RJ01 | Rejection of invention patent application after publication |